Executive summary
US Patent 12,594,267 is a formulation patent centered on a specific injectable-style liquid composition defined by (i) a sodium salt of a compound of Formula (Ia), (ii) water, and (iii) PEG 300, with the composition constrained to narrow weight-percent bands and “about” tolerances. The claim set is structured as a Markush-free composition definition with (a) broad band claims (claims 1, 2-5, 7, 12) and (b) narrower exemplified/locked-in embodiments (claims 6, 8-11, 10). The enforceable scope is therefore driven less by the underlying drug chemistry and more by manufacturing/prescription-time product makeup: competitors must avoid using the sodium salt of Formula (Ia) in the recited PEG 300/water ranges and “about” tolerances.
H1: US Patent 12,594,267 sodium salt PEG 300 water formulation claims scope
What does US 12,594,267 claim cover: sodium salt of Formula (Ia) + PEG 300 + water
Direct claim core (composition-by-ingredients and composition-by-percent). Claim 1 defines “a pharmaceutical composition” that is a solution containing:
- the sodium salt of a compound of Formula (Ia),
- water, and
- PEG 300,
with weight-percent ranges:
- water: ~20 to ~30 w/w %
- PEG 300: ~48 to ~60 w/w %
- sodium salt of Formula (Ia): ~11 to ~28 w/w %
And it defines the meaning of “about” as +5 w/w %.
Claim 1 structural elements that matter for scope
-
Sodium salt only
The claims require the active to be the sodium salt of the Formula (Ia) compound. A potassium salt, free base, different counterion, or a different salt form is not within the literal wording unless it is argued to be within claim interpretation doctrines (not specified here).
-
Solution form
Claim 1 requires a solution. That typically constrains to compositions where the sodium salt is solubilized/dispersed such that the mixture is properly characterized as a solution.
-
Tri-component system
The claims recite only three components: sodium salt, water, and PEG 300. The wording does not explicitly exclude other excipients, but claim interpretation often treats the defined ranges as applying to the listed components. If a competitor adds meaningful excipients, infringement hinges on whether the product still “consists of” the claimed solution (see claims 5-11) or just “consists of” in the broader/comprising sense.
Quantitative “about” expansion for Claim 1
Claim 1 uses “about” = +5 w/w %. That expands each stated band:
- water band (20-30) becomes effectively 15-35 w/w %
- PEG 300 band (48-60) becomes effectively 43-65 w/w %
- sodium salt band (11-28) becomes effectively 6-33 w/w %
Because the solution must sum to 100 w/w %, practical overlap narrows. Still, for design-around, the operative fact is that Claim 1’s tolerance is wide enough to capture multiple nearby formulations.
Which claim variants narrow the composition range: 20–30% water, 48–60% PEG 300, 11–28% sodium salt
Claims 2–4 target single-variable subranges inside the Claim 1 framework:
- Claim 2: water about 21–29%
- Claim 3: PEG 300 about 50–59%
- Claim 4: sodium salt about 13–27%
Each is dependent on claim 1 (so it inherits the “about” definition from claim 1 unless overridden).
How the dependent claims change infringement posture
A competitor can attempt to land outside one component range while remaining inside others. But since Claim 1 is broad on each component, a design-around must typically clear Claim 1 itself. If any accused product falls within the Claim 1 expanded bands after applying the “about” tolerance, the dependent narrowing claims are not the main risk driver.
“About” tolerance override (Claim 12)
- Claim 12: “about refers to +3 w/w %.”
Because Claim 12 depends on claim 1, this likely narrows tolerance for that specific dependent claim. The independent enforcement risk depends on which claim is asserted. If litigation targets only claim 12, the effective bands tighten.
Practical impact of “about” = +3 w/w % (Claim 12)
For claim 12:
- water effectively 17–33%
- PEG 300 effectively 45–63%
- sodium salt effectively 8–31%
Again, sum-to-100 constraints apply, but the tolerance reduction matters for close variants.
What formulations are “consisting of” PEG300/water/sodium salt: claims 5–11
Claims 5–11 use “wherein the solution consists of” / “composition consists of” language, which is materially stronger for narrowing. These claims limit the formulation to the stated components at the stated ranges (and in “consists of” form, leaving less room for additional excipients).
Claim 5 (three-range recital, “consists of”)
- water 21–29%
- PEG 300 50–59%
- sodium salt 13–27%
This is a narrower “consists of” version of the Claim 1 ranges.
Claim 6 (locked-in point values)
- water 23.41%
- PEG 300 50.13%
- sodium salt 26.46%
This is a precise embodiment. If an accused formulation matches these exact percentages, it is a direct literal target. Even if not exact, it can still matter in doctrine-of-equivalents arguments depending on claim construction outcomes.
Claims 8–9 (tighter bands)
- Claim 8: water 22.2–24.6%, PEG 300 47–53%, sodium salt 25.1–27.8%
- Claim 9: same ranges as claim 8
These are tighter than Claim 5 on water and sodium salt.
Claims 10–11 (repeated exact and single-number embodiments)
- Claim 10: repeats the locked-in values of claim 6
- Claim 11: water about 23%, PEG 300 about 50%, sodium salt about 27%
Claim 11’s “about” tolerance is not explicitly restated; it inherits from claim 1 unless claim 12 (or claim 13) applies to it via explicit linkage, which is not shown in the provided excerpt.
How strong is the patent estate for this drug: what depends on having the sodium salt and PEG300 solution
Strength is concentrated in a narrow formulation space. With only the provided claim text, the enforceability profile is as follows:
-
High value on product mix
If the commercial product uses sodium salt of Formula (Ia) in PEG 300/water solution within the bands, infringement risk is high.
-
Design-around is feasible but constrained
A generic or follow-on formulation can reduce risk by:
- changing the salt form (non-sodium counterion),
- changing the solvent system (replace PEG 300, or substantially shift water/PEG ratios),
- changing the delivery form away from a “solution,” or
- moving outside the “about” tolerances.
-
“Consists of” claims reduce excipient latitude
Claims 5–11 can be a bigger litigation hook if an accused formulation uses additional components that an applicant would otherwise argue are harmless. Under “consists of,” the competitor’s ability to add excipients without leaving the scope is constrained by claim construction.
What patents protect the active ingredient versus only the PEG 300 formulation
This patent, as reflected by the claim language, protects the formulation composition, not broadly the molecule. The claims reference:
- “a compound of Formula (Ia),” but
- the sodium salt form,
- in PEG 300/water solution at specific ratios.
That means the patent’s commercial protection is typically strongest for:
- liquid/solution manufacturing using PEG 300 as a major component,
- sodium-salt-containing compositions.
If other patents exist (not provided) covering the base compound, polymorphs, process, or use, they would add layers of protection beyond the composition bands in US 12,594,267. But based solely on the claim excerpt, this patent’s scope is formulation-specific.
How many distinct claim “windows” are there for infringement risk
Using the provided claim set, there are multiple overlapping windows:
-
Broadest window: Claim 1
- water ~20–30%
- PEG 300 ~48–60%
- sodium salt ~11–28%
- “about” = +5 w/w %
-
Narrower single-variable windows: Claims 2–4
These carve sub-bands but remain dependent on claim 1.
-
Narrowest “consists of” windows: Claims 5, 8–9
Each has stricter combinations and, in claim 5, narrower water/PEG/salt bands than claim 1.
-
Locked-in embodiments: Claims 6 and 10
Exact or near-exact points.
-
Tighter “about” tolerance: Claim 12 and 13
Claim 12 sets about = +3 w/w % (and claim 13 repeats about = +3 w/w % in claim 6 context).
From a litigation targeting perspective, asserting Claim 1 captures the widest net; asserting Claims 5–11 supports product-mix-specific infringement narratives.
What generic entry risks exist for a competitor reformulating around US 12,594,267
Risk depends on whether the competitor keeps PEG 300 and the sodium salt and lands within weight-percent bands.
Common design-around pathways
- Switch counterion: sodium salt to another salt form to exit “sodium salt” literal requirement.
- Change PEG 300 content: move PEG 300 outside the ranges, accounting for “about.”
- Change water content: adjust to outside the water band.
- Change “solution” behavior: if the system is made into a different physical form, the “solution” limitation becomes relevant.
- Add excipients strategically: “consists of” claims 5–11 can become harder to avoid if excipients are not allowed or if the product still satisfies the “consists of” constraint under claim construction.
Where the “about” term matters for product substitution
- If an accused formulation is near the edges of the bands, whether “about” is treated as +5 or +3 changes infringement risk materially.
- If the asserted claim is Claim 12 or Claim 13 (both set “about” = +3), close variants have more room to argue outside the recited meaning of “about.”
When does this formulation patent lose exclusivity? What is the expiration date?
No filing, priority, or patent term data for US 12,594,267 is included in the provided information, so an exclusivity/expiration date cannot be computed from the claim excerpt.
What Orange Book status does US 12,594,267 have
No FDA product, Orange Book listing, or drug identity information is provided in the prompt. Without that, Orange Book status cannot be determined from the excerpt.
What Paragraph IV or biosimilar challenges apply
The claim excerpt does not identify:
- the reference listed drug (RLD),
- the NDA/BLA number,
- any listed patents in the Orange Book,
- any FDA compatibility with a generic or biosimilar pathway.
No Paragraph IV or biosimilar challenge mapping can be derived from the provided text alone.
What manufacturing/IP barriers does PEG 300 solution imply for generic scale-up
This formulation class suggests:
- a requirement to control water and PEG 300 ratios precisely by weight,
- maintenance of the sodium salt form during manufacturing,
- ensuring the product remains a solution rather than precipitating.
For litigation, the key proof points typically include batch records and analytical results showing the exact w/w ratios and salt identity at release.
Key Takeaways
- US 12,594,267 protects a specific sodium-salt PEG 300/water solution defined by w/w % ranges and a defined meaning of “about.”
- Claim 1 is the broadest enforcement anchor: water ~20–30%, PEG 300 ~48–60%, sodium salt ~11–28%, with “about” = +5 w/w %.
- Claims 5, 8–9 use “consists of” language that tightens permissible formulation composition.
- Claims 6 and 10 lock in exact weight percentages, creating a direct infringement target if a product matches.
- Claims 12–13 narrow the “about” tolerance to +3 w/w % in those dependent contexts, which can create meaningful design-around headroom for near-edge formulations.
FAQs
-
If a competitor uses PEG 400 instead of PEG 300, does it avoid US 12,594,267?
A PEG 400-based solvent system does not meet the PEG 300 limitation in the literal claim language.
-
How much can a formulation vary from the stated percentages without falling outside the claims?
The claims define “about” as +5 w/w % in claim 1 and as +3 w/w % in claim 12 (and claim 13 for the dependent context). That drives edge-case infringement analysis.
-
Do claims 5–11 allow additional excipients beyond sodium salt, water, and PEG 300?
“Consists of” language constrains formulation composition more than open-ended wording, making additional components a potential infringement and claim-construction issue.
-
Can switching from the sodium salt to another salt form avoid infringement?
The claims require “the sodium salt” of a compound of Formula (Ia), so non-sodium salts are the primary literal design-around lever.
-
Which single claim is most likely to be asserted for broad coverage?
Claim 1, because it provides the widest bands and defines the primary “about” tolerance (+5 w/w %).
References (APA)
[No citable sources were provided in the prompt.]
